Skip to main content
Premium Trial:

Request an Annual Quote

Odyssey Thera Signs Cell-Based Assay Services Agreement with Lexicon Genetics

NEW YORK, June 20 (GenomeWeb News) - Odyssey Thera has signed a services agreement with Lexicon Genetics under which it will characterize the pathway activity of certain Lexicon compounds in human cells.

 

Odyssey Thera said it will apply its protein-fragment complementation assay (PCA) technology to study the on-pathway and off-pathway activities of compounds in living human cells.

 

The company said that it uses a database of known drugs and toxic compounds in order to compare the activity of novel compounds with the activities of marketed and withdrawn agents and toxicants.

 

Financial terms of the agreement with Lexicon were not provided.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.